Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats - PubMed (original) (raw)

. 2006 Oct;291(4):E860-6.

doi: 10.1152/ajpendo.00366.2005. Epub 2006 May 16.

Affiliations

• PMID: 16705058
• DOI: 10.1152/ajpendo.00366.2005

Free article

Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats

Renée P Kinman et al. Am J Physiol Endocrinol Metab. 2006 Oct.

Free article

Abstract

A new chronic treatment for inherited disorders of long-chain fatty acid oxidation involves administering up to one-third of dietary calories as triheptanoin, a medium-odd-chain triglyceride (Roe CR, Sweetman L, Roe DS, David F, and Brunengraber H. J Clin Invest 110: 259-269, 2002). Heptanoate and C(5)-ketone bodies derived from its partial oxidation in liver are precursors of anaplerotic propionyl-CoA in peripheral tissues. It was hypothesized that increasing anaplerosis in peripheral tissues would boost energy production. In the present study, we tested the potential of a triheptanoin emulsion as an intravenous nutrient. Normal rats were infused with triheptanoin intravenously or intraduodenally at up to 40% of caloric requirement. The blood concentration ratio (heptanoate/C(5)-ketone bodies) was high with intravenous and low with intraduodenal triheptanoin infusion. During intravenous infusion of triheptanoin, lipolysis was stimulated but appeared compensated by fatty acid reesterification. During intraduodenal infusion of triheptanoin, lipolysis was not stimulated. Our data support the hypothesis that intravenous triheptanoin could be used to treat decompensated patients with long-chain fatty acid oxidation disorders.

PubMed Disclaimer

Similar articles

• Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats. II. Effects on lipolysis, glucose production, and liver acyl-CoA profile.
  Gu L, Zhang GF, Kombu RS, Allen F, Kutz G, Brewer WU, Roe CR, Brunengraber H. Gu L, et al. Am J Physiol Endocrinol Metab. 2010 Feb;298(2):E362-71. doi: 10.1152/ajpendo.00384.2009. Epub 2009 Nov 10. Am J Physiol Endocrinol Metab. 2010. PMID: 19903863 Free PMC article.
• Cardiac tissue citric acid cycle intermediates in exercised very long-chain acyl-CoA dehydrogenase-deficient mice fed triheptanoin or medium-chain triglyceride.
  Gaston G, Gangoiti JA, Winn S, Chan B, Barshop BA, Harding CO, Gillingham MB. Gaston G, et al. J Inherit Metab Dis. 2020 Nov;43(6):1232-1242. doi: 10.1002/jimd.12284. Epub 2020 Aug 4. J Inherit Metab Dis. 2020. PMID: 33448436
• The Pharmacokinetics of Triheptanoin and Its Metabolites in Healthy Subjects and Patients With Long-Chain Fatty Acid Oxidation Disorders.
  Lee SK, Gupta M, Shi J, McKeever K. Lee SK, et al. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1325-1334. doi: 10.1002/cpdd.944. Epub 2021 Mar 31. Clin Pharmacol Drug Dev. 2021. PMID: 33789001 Free PMC article. Clinical Trial.
• Implications of impaired ketogenesis in fatty acid oxidation disorders.
  Olpin SE. Olpin SE. Prostaglandins Leukot Essent Fatty Acids. 2004 Mar;70(3):293-308. doi: 10.1016/j.plefa.2003.06.003. Prostaglandins Leukot Essent Fatty Acids. 2004. PMID: 14769488 Review.
• Triheptanoin: First Approval.
  Shirley M. Shirley M. Drugs. 2020 Oct;80(15):1595-1600. doi: 10.1007/s40265-020-01399-5. Drugs. 2020. PMID: 32897506 Free PMC article. Review.

Cited by

• Anaplerotic Therapy Using Triheptanoin in Two Brothers Suffering from Aconitase 2 Deficiency.
  Penkl M, Mayr JA, Feichtinger RG, Reilmann R, Debus O, Fobker M, Penkl A, Reunert J, Rust S, Marquardt T. Penkl M, et al. Metabolites. 2024 Apr 20;14(4):238. doi: 10.3390/metabo14040238. Metabolites. 2024. PMID: 38668366 Free PMC article.
• Intranasal delivery of mitochondria targeted neuroprotective compounds for traumatic brain injury: screening based on pharmacological and physiological properties.
  Pandya JD, Musyaju S, Modi HR, Okada-Rising SL, Bailey ZS, Scultetus AH, Shear DA. Pandya JD, et al. J Transl Med. 2024 Feb 16;22(1):167. doi: 10.1186/s12967-024-04908-2. J Transl Med. 2024. PMID: 38365798 Free PMC article. Review.
• Heptanoic and medium branched-chain fatty acids as anaplerotic treatment for medium chain acyl-CoA dehydrogenase deficiency.
  Karunanidhi A, Basu S, Zhao XJ, D'Annibale O, Van't Land C, Vockley J, Mohsen AW. Karunanidhi A, et al. Mol Genet Metab. 2023 Nov;140(3):107689. doi: 10.1016/j.ymgme.2023.107689. Epub 2023 Aug 25. Mol Genet Metab. 2023. PMID: 37660571 Free PMC article.
• Lipidomic and Proteomic Alterations Induced by Even and Odd Medium-Chain Fatty Acids on Fibroblasts of Long-Chain Fatty Acid Oxidation Disorders.
  Alatibi KI, Tholen S, Wehbe Z, Hagenbuchner J, Karall D, Ausserlechner MJ, Schilling O, Grünert SC, Vockley J, Tucci S. Alatibi KI, et al. Int J Mol Sci. 2021 Sep 29;22(19):10556. doi: 10.3390/ijms221910556. Int J Mol Sci. 2021. PMID: 34638902 Free PMC article.
• Development and validation of a LC-MS/MS method for quantitation of 3-hydroxypentanoic acid and 3-oxopentanoic acid in human plasma and its application to a clinical study of glucose transporter type I deficiency (G1D) syndrome.
  Kallem RR, Primeaux S, Avila A, Pascual JM, Putnam WC. Kallem RR, et al. J Pharm Biomed Anal. 2021 Oct 25;205:114335. doi: 10.1016/j.jpba.2021.114335. Epub 2021 Aug 27. J Pharm Biomed Anal. 2021. PMID: 34482182 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information